Rare Disease specialist with focus on building, leading, and developing successful teams. Knowledge, skills and experience in past 15 years focus specifically on rare disease and ultra-orphan space in both sales leadership and sales roles with an emphasis on successful product launches.26 years of successful experience in Biotechnology, Pharmaceutical, and Medical/Surgical industry with a specific focus on Sales Leadership, Direct Sales, Managed Care, National Accounts, Training, Reimbursement Program Design, and Consulting.Launched and/or promoted 7 new rare disease treatments including 6 with a patient incidence of less than 200,000 and 4 ultra-orphan treatments with a patient incidence of less than 3,500.-Synagis for RSV (as a Reimbursement and Program Consultant).-GLIADEL Wafer, a neuro-oncology/neurosurgery treatment for high-grade malignant brain tumors. Incidence is 3,500 patients in Untied States.-Dacogen, a treatment for myelodysplastic syndromes. Incidence is 60,000 patients in United States.-VPRIV, an Enzyme Replacement Therapy for Gaucher Disease (Lysosomal Storage Disorder). Incidence is 2,000 patients in United States.-Elaprase, an Enzyme Replacement Therapy for Hunter Syndrome/ MPS II (Lysosomal Storage Disorder). Incidence is 500 patients in United States. -Tegsedi, a new antisense oliogonucleotide for the treatment of hereditary transthyretin amyloidosis with polyneuropathy. Incidence is 3,500 patients in United States.-Waylivra, a new antisense oliogonucleotide for the treatment of Familial Chylomicronemia Syndrome (pre-launch activities; CRL received from FDA). Incidence is 750 patients in United StatesExceptional business acumen, clinical knowledge, and sales leadership expertise with an emphasis on strong work ethic, positive attitude, and accountability. Extensive experience with Specialty Pharmacies, Buy and Bill Models, Managed Care, Patient Services Hubs, Infusions, and Injectables.